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Abstract: Consider a gene expression array study comparing two groups of subjects where the goal is to explore a large 
number of genes in order to select for further investigation a subset that appear to be differently expressed. There has been 
much statistical research into the development of formal methods for designating genes as differentially expressed. These 
procedures control error rates such as the false detection rate or family wise error rate. We contend however that other 
statistical considerations are also relevant to the task of gene selection. These include the extent of differential expression 
and the strength of evidence for differential expression at a gene. Using real and simulated data we ﬁ  rst demonstrate that a 
proper exploratory analysis should evaluate these aspects as well as decision rules that control error rates. We propose a new 
measure called the mp-value that quantiﬁ  es strength of evidence for differential expression. The mp-values are calculated 
with a resampling based algorithm taking into account the multiplicity and dependence encountered in microarray data. In 
con  trast to traditional p-values our mp-values do not depend on speciﬁ  cation of a decision rule for their deﬁ  nition. They are 
simply descriptive in nature. We contrast the mp-values with multiple testing p-values in the context of data from a breast 
cancer prognosis study and from a simulation model.
Introduction
In a gene expression array experiment, the expression levels of thousands of genes are monitored 
simultaneously. In cancer research the purpose of such a study is often to identify transcripts that show 
differential expression levels in cancer tissues as compared to normal tissues. This information may 
help to pinpoint the biological processes for cancer or to discover cDNAs encoding proteins that could 
be useful for cancer screening or diagnosis. Another common purpose is to compare gene expression 
in subjects with good and poor prognosis after being diagnosed with cancer. This information may help 
predict outcome for cancer patients and develop more speciﬁ  c treatment strategies. For example, in a 
study concerning gene expression proﬁ  ling and clinical outcome of breast cancer (Van’t Veer, 2002), 
tumor tissue from 34 patients who developed distant metastases within 5 years and 44 patients who 
were free of disease for at least 5 years were analyzed to compare the hybridizations on an array of 
25,000 cDNAs.
Statistical analysis of data from such studies is challenging. Moreover, it is important to recognize 
that an appropriate statistical approach depends on the scientiﬁ  c objectives of the study. In this article, 
we consider microarray studies that are aimed to explore a large pool of genes and select for more 
careful investigation a subset of genes that are differentially expressed. There has been much research 
into formal multiple hypothesis testing procedures for designating genes as differentially expressed. 
Procedures that control error rates have been a main focus of statistical research. Dudoit, Shaffer and 
Boldrick (2002) provide a review. Less attention however has been paid to other statistical aspects of 
the analysis that we feel are important. For example, the form and extent of differential expression at a 
gene are often important. If the difference in gene expression is not of sufﬁ  cient magnitude or form to be 
useful, then such a gene should not be selected. Another issue is to characterize the strength of evidence 
for differential expression at a gene. In this paper we discuss the many aspects of assessing differential 
gene expression. We also propose a new descriptive measure, a probability that quantiﬁ  es the strength 
of evidence for differential expression in a natural and intuitive fashion. In data analysis section we 
illustrate with real and simulated data how extent and evidence for differential expression can be used 
in conjunction with formal multiple hypothesis testing procedures to select genes for further study.
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Error controlling decision rules
Recognizing the exploratory nature of gene ﬁ  nding 
studies and the high potential for erroneous con-
clusions based on standard univariate hypothesis 
testing procedures, statisticians have spent much 
effort on developing multivariate hypothesis test-
ing procedures that control error rates. The multiple 
hypothesis testing paradigm is usually formulated 
as follows. Each of the m genes on the microarray 
is considered to correspond to a single hypothesis 
test. Rejecting an hypothesis test is equivalent to 
claiming that the gene is differentially expressed. 
In Table 1 we suppose m0 of the m genes are not 
differentially expressed, i.e. are null hypotheses. 
Denote by R the number of rejected hypotheses, V0 
the number of false positives, and V1 the number 
of false negatives. Only m and R are observable 
quantities.
An appropriate test procedure aims to keep both 
V0 (the type I error) and V1(the type II error) small. 
In the univariate setting, the usual strategy is to 
pre-specify an acceptable type I error rate, α, then 
seek a decision rule with the smallest type II error 
among those with type I error α. To generalize to 
the multivariate setting, the approach is to deﬁ  ne a 
multiple testing procedure in terms of an adjusted 
p-value, p ˜j, for hypothesis j. The adjusted p-value,  
p ˜j , is different from the individually unadjusted 
p-value pj in that p ˜ j takes all other hypothesis tests 
that are involved into consideration. One then 
rejects Hj if  p ˜j ≤ α.
The adjusted p-values are derived so that some 
type I error rate is controlled at level α. The family-
wise error rate (FWER), is deﬁ  ned as
 FWER = P(V0 ≥ 1),  (1)
is the probability of at least one false positive 
(type I error). The step-down algorithm of Westfall 
and Young (1993) is an example of a multiple test-
ing procedure that controls FWER. The procedure 
deﬁ  nes the jth adjusted p-value as p ˜j = P[min1≤l≤m 
Pl ≤ pj|H0
c ]. Here H0
c  denotes the complete null 
hypothesis, where all the null hypotheses are true 
(i.e. m = m0) and Pl is the unadjusted p-value for 
the l
th hypothesis denoted with capital letter here 
because it is a random variable. The joint distribu-
tion of ( P1, ..., Pm) can be estimated by permuting 
the columns of the gene by array data matrix. This 
algorithm thus takes into account the potential 
dependence structure amongst genes but requires 
the so-called ‘subset pivotality’ property that is 
described in Dudoit, Shaffer and Boldrick (2002) 
(a complex and unintuitive notion). The popular 
but extremely conserva  tive Bonferroni procedure 
deﬁ  nes the adjusted p-values as p ˜j = pj /m. The 
Westfall and Young approach is less conserva-
tive. Recently, even less stringent procedures have 
been proposed (Dudoit et al. 2004; van der Laan 
et al. 2004; Lehmann and Romano, 2003) that are 
designed to control the generalized family-wise 
error rate (gFWER):
 gFWER  = P(V0 ≥ c). (2)
Benjamini and Hochberg (1995) suggested a 
multiple testing procedure that aims to control a 
different type I error rate, the false discovery rate 
(FDR). In their deﬁ  nition,
  FDR = E(V0/R|R > 0)P(R > 0)  (3)
The concept of FDR is appealing in the context 
of gene discovery. It is the expected proportion 
of false positives among genes for which H0 is 
rejected, an intuitive and directly useful quantity. 
Moreover it can be less stringent than controlling 
FWER or gFWER.
Several procedures have been proposed to 
control FDR. For example, Benjamini and Hoch-
berg (1995) described a linear step-up procedure. 
Suppose we order the unadjusted p-values as 
Table1.The classic hypothesis testing frame work for gene selection. Non-null hypotheses correspond to 
differentially expressed genes.
   # not rejected  # rejected  total
#null hypotheses  m0 – V0  V0  m0
#non-null hypotheses  V1  S  m – m0
total  m – R  R  mCancer Informatics 2007:3 205
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p(1)  ≤  p(2)     ... ≤  p(m), with corresponding ordered null 
hypotheses H(1), H(2), ..., H(m). The adjusted p-value for 
H(j) is   pp j
BH
kjm
m
k k ( ) ,... ( ) min {min( , } = = 1 . We reject H(1), 
..., H(k) for k = max {: } () jp j
BH  ≤α  for a desired FDR 
level α. It can be shown that under some assump-
tions, the procedure yields FDR = α * m0 /m, 
which is ≤ α (Benjamini and Yekutieli, 2001). 
When m0 /m is substantially smaller than 1, it is 
tempting to consider an adaptive procedure so 
that FDR is controlled exactly at level α. Storey 
(2002) suggested to ﬁ  rst estimate m0, and reject 
H(1), ..., H(k) for k = max{  j:  p j
BH
()* ˆ / mm 0 ≤α}. To 
estimate m0, Storey suggested
  ˆ ()
{}
m
Ip i
m
I
0
1
1
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λ
λ
=
≥
−
= Σ  (4)
where λ is in the interval (0, 1) and can be chosen 
using cross-validation, for example. The adaptive 
procedure is usually more powerful because it is 
less conservative, being based on the bound 
m
m ˆ0 α α 
rather than α for   p j
BH
() .
Other formal error rate controlling procedures 
have been proposed (see Dudoit, Shaffer and Bold-
erick (2004) for examples) but the Westfall and 
Young (1993), Benjamini and Hochberg (1995) 
and Storey (2002) procedures mentioned above 
are currently most popular.
Extent of differential expression
The fundamental component of any hypothesis 
testing procedure is the test statistic. Suppose 
that for gene g, expression data {Yg j
C , j =1, ... 
nC} are measured on nC normal tissues and 
{Yg j
D ,i = 1, ... nD} cancer tissues. The test statistic 
implicitly deﬁ  nes the metric by which differential 
expression is quantiﬁ  ed. Genes are typically ranked 
from highest (rank = 1) to lowest (rank = m) accord-
ing to the test statistic. Thus, the whole meaning of 
differential expression between the populations of 
cancer subjects and non-cancer subjects is based on 
the test statistic. The larger the statistic is, the more 
differentially expressed {Ygi,i = 1, ..., nD} versus 
{Ygj, j = 1, ... nC} are considered. Genes that rank 
high with one measure of differential expression 
(test statistic) may rank low when another test sta-
tistic is used to quantify differential expression.
Despite its crucial role in selecting genes, there 
has been little discussion about what constitutes an 
appropriate test statistic. The Welch’s t-statistic is 
most commonly applied
  WYY
s
n
s
n
DC
D
D
C
C
=- + () /
2 2
 
where Y and s
2 denote sample means and variances. 
We suspect that widespread familiarity with the 
t-test among biologists is primarily responsible for 
its popularity. As far as we know it has not been 
promoted as more appropriate than other two-
sample statistics for the purposes of quantifying 
differential expression.
On the other hand there have been some argu-
ments put forth for alternatives to the t-test (Lyons-
Weiler et al. 2004; Pepe et al. 2003). For example, 
Lyons-Weiler et al. (2004) argued that while the 
t-test had been widely used for identifying popula-
tion-level biomarkers, it could miss markers that 
might be important to a subset of patients. They 
developed a permutation percentile separability 
(PPST) test to identify important genes that are 
dysregulated in only a fraction of patients. For 
simplicity, suppose that larger values of Yg are 
associated with cancer. One might consider the 
sensitivity and speciﬁ  city of classiﬁ  cation to cancer 
based on the expression level: ‘Yg > threshold.’ The 
receiver operating characteristic (ROC) curve, a 
plot of the sensitivity versus 1-speciﬁ  city with all 
possible thresholds, can be used to characterize the 
separation between the distributions of the gene ex-
pression levels for cancerous tissues and for normal 
tissues. Many summary measures of discrimination 
that are commonly used in ROC curve analysis can 
be considered. The “tail rank statistic” is the true 
positive rate (TPR or sensitivity) of the classiﬁ  er 
that uses as threshold, the 100 × (1 – f0) percentile 
of Yg in the non-cancer population, denoted by 
Zg
C(f0). If values below Zg
C(f0) are considered within 
normal range, the TPR is the proportion of cases 
with abnormal expression at gene g. By deﬁ  nition 
the false positive rate (FPR = 1–speciﬁ  city) of this 
rule is f0. We write the statistic as
  TPR f I Y Z f n gg i
D
i
n
g
C
D
D
() [ ˆ () ] / 0
1
0 =≥
= ∑ , 
where  ˆ Zg
C(f0) is the observed percentile of Yg in the 
non-cancer tissues and I [ ] is the indicator func-
tion equal to 1 if [ ]is true. The tail-rank statistic, 
TPRg ( f0), is also known as the empirical estimate 
of the ROC curve at FPR = f0, ROC( f0). Pepe 
et al. (2003) propose to rank genes according to 
ROC (f0). Alternatively one could ﬁ  x the true positive Cancer Informatics 2007:3 206
Zheng and Pepe
rate at t0 say, and compare genes in regards to the 
corresponding false positive rates
  FPR t I Y Z t n t gg j
c
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c
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where  ˆ Zg
D(t0) is the (1 – t0) percentile of Yg in the 
cancer tissues. Lyons-Weiler et al. (2004) propose 
to select genes using both TPRg(t0) and FPRg(t0).
When a range of false positive (or true positive) 
rates is of interest, e.g. f ≤ f0, the corresponding 
true positive rates can be averaged. The average 
true positive rate (( ) ) TPR f g 0 , can be written in 
the following equivalent ways
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where pAUCg( f0) denotes the partial area under the 
ROC curve for gene g (Dodd and Pepe, 2004). This 
statistic is discussed in Pepe et al. (2003) for the 
purposes of gene selection in microarray studies. 
Interestingly with an unrestricted range of false 
positive rates, i.e. f0 = 1, the averaged true positive 
rate is the area under the ROC curve (AUC), also 
known as the expected Mann-Whitney two sample 
U-statistic: AUC =
0
1
∫  ROC(t)dt = P(Y 
D > Y 
C). Since 
the Mann-Whitney statistic is a simple function of 
the Wilcoxon rank sum statistic, it follows that us-
ing the popular nonparametric Wilcoxon statistic as 
the basis of gene ranking is the same as choosing 
the AUC as its basis. Lee et al. (2005) recommend 
using the Wilcoxon statistic to rank genes.
One important advantage of statistics 
like TPRg( f0), TPRg( f0) and AUC is that they are 
inherently com  parable across genes. Clearly this 
is necessary for procedures that rank genes on the 
basis of a statistic. Their non-parametric nature 
implies that they do not depend on the distribu-
tions of the raw expression levels, Yg, for cancer 
and non-cancer tissues. They are invariant to 
monotone transformations of the raw data. This 
property makes them appealing for comparisons 
across genes and hence for ranking. In contrast, 
Welch’s t-statistic depends directly on the raw 
expression levels. For example taking the logarithm 
of the raw data values will change the value of 
W but it will leave TPRg( f0), TPRg (f0) and AUC 
unchanged. Moreover, W weights σD and σC 
according to 1/nD and 1/nC, respectively, in its 
denominator. Thus, if the availability of data for 
two genes are such that nD or nC differ, their W 
statistics will differ even if values of YYs DCD ,,
2 and 
sC
2  are the same. In our opinion it is a mistake to 
allow sample sizes to enter into the measure and 
meaning of differential expression chosen for gene 
ranking. The sample sizes are usually chosen by 
design and are affected by missingness that can 
vary across genes.
Interestingly, when data are normally distributed 
for cases and for controls, it can be shown that
  AUC Y Y s s
DC
DC =− + ⎡
⎣
⎤
⎦
Φ () / .
22  
where Φ is the standard normal cumulative distri-
bution function. Therefore, Welch’s t-statistic can 
be regarded as a scaled estimate of Φ
–1(AUC) that 
equalizes the number of cases and controls.
In our illustration and simulations we use 
TPR(f0), and AUC to compare genes in regards to 
differential expression. In practice one may want 
to examine several measures of discrimination 
in selecting genes to study further. For example, 
one might seek genes for which AUC is large 
and for which TPR(0.2) is large. Although the 
latter statistic is not as stable as AUC, it is more 
meaningful for classification. Formal multiple 
hypothesis testing procedures do not consider 
the possibility of evaluating simultaneously 
multiple measures of differential expression. 
In the spirit of the exploratory nature of such 
studies however it seems that such evaluations 
should be encouraged.
Evidence for differential expression
Consider the ranked list of genes, ranked on the 
basis of a statistic T (or the associated p-value). 
Randomness caused by sampling variability im-
plies that, T, considered as the estimated extent 
of differential expression, is biased after ranking. 
Even if there were no differential expression for 
any gene, one would expect the statistics for the 
highest ranking genes to be large. But how large? 
How to calibrate the observed statistics for random 
chance? There are various ways one might address Cancer Informatics 2007:3 207
Selecting Differentially Expressed Genes
this. One proposal is to calculate the probability 
that T(g) would exceed the observed value if it and 
all lower ranking genes were not differentially 
expressed. Speciﬁ  cally we propose to calculate the 
mp-value deﬁ  ned for the g
th ranking gene as
 mp-value (g) = P[T(g) ≥ t(g) | H0j,(j) ≥ g]. 
The notation H0j, (j)≥g means that the mp-value 
is calculated assuming that genes ranked at or 
below the g
th are not differentially expressed. It 
is the probability that amongst these m – g + 1 
genes, the maximum statistic,max( )
()
T
jg
j
≥ would exceed 
the observed value for the g
th ranking gene, t(g). It 
provides a measure of how extreme is the observed 
value in the setting where none of the lower ranking 
genes, (j) ≥ g, are differentially expressed. If the 
mp-value is low, it provides evidence that at least 
the g
th gene must be differentially expressed.
In the classic framework of hypothesis testing, 
where only one statistic is under consideration 
(rather than many), the p-value has two equivalent 
interpretations. It is the probability that a statistic 
as large as that observed in the data would be 
observed if the null hypothesis were true. It is 
equivalently the lowest type I error rate for the 
hypothesis rejection rule that uses T as its basis. 
When multiple hypotheses and statistics are under 
consideration, adjusted p-values have been deﬁ  ned 
to generalize the latter notion. This was described 
in the previous section. On the other hand, our ad-
justed mp-value generalizes the former univariate 
concept of p-value to the multiple statistic setting. 
An appealing attribute of our mp-value deﬁ  nition 
is that it is not tied to any particular decision rule 
for rejecting hypotheses (i.e. selecting genes). It is 
simply a descriptive measure of evidence in favor 
of differential expression.
We suggest estimating mp-value for the g
th gene 
using a resampling procedure that avoids assump-
tions about the joint distribution of test statistics 
and takes into account the dependence structure 
among genes. The resampling procedure essen-
tially compares the observed statistic of interest 
with the distribution of the statistic obtained under 
the random condition assuming that no gene is dif-
ferentially expressed. Speciﬁ  cally one can:
1. Compute the order statistics t(1) ≥ t(2)··· ≥ t(m). 
Let I(g) denote indices of genes ranking at or 
below the g
th ranking gene.
2. Perform B permutations of the cancer versus 
non-cancer group labels and obtain {Tj,b; j = 1, 
...m} for each permutation sample b.
3. Compute the estimate
  mp g
B
Tt jb g
jg b
B
( ) max( ) ,( )
()
=≥ []
= ∑
1
1
I
εI
 
Data Analysis
Simulated data
We  ﬁ  rst illustrate our methods using simulated 
data. The advantage of using simulated data 
is that we know the truth underlying the data 
and therefore we have a gold standard against 
which to compare results. Results in Table 2 are 
from a scenario where 100 genes are differen-
tially expressed and 1900 genes are not. The gene 
expression values were simulated from a standard 
normal distribution for 50 controls and from either 
a standard normal (the 1900 non-differentially 
expressed genes) or a normal with mean and stan-
dard deviation equal to 1.5 (the 100 differentially 
expressed genes) for 50 cases. In this simula-
tion model, expression values are statistically 
independent across genes.
For differentially expressed genes the true-
positive rate corresponding to the positivity rule 
that yields a 20% false-positive rate is 67%. That 
is, TPR( f0) = 0.67 when f0 = 0.20. The area under 
the ROC curve (AUC) is 0.80. Table 2 shows 
results for subsets of the highest ranking genes, 
when genes were ranked according to the statis-
tic TPR( f0) calculated for one simulated dataset. 
Interestingly, the 100 differentially expressed genes 
all ranked above the non-differentially expressed 
genes in this dataset.
First let us consider the magnitudes of the 
statistics. Among the top 100 ranked genes, the 
estimates TPR( f0) ranged from a minimum of 0.56 
to a maximum of 0.88 and the AUC ranged from 
0.718 to 0.912. If an investigator seeks genes for 
which the data suggest complete separation of 
cancer versus non-cancer tissues, the results are 
disappointing. For no gene is TPR( f0) = 1 or is the 
AUC = 1. Although we ﬁ  nd the statistic TPR( f0) 
most interpretable and meaningful, gauging the 
potential usefulness of a TPR( f0) value depends en-
tirely on the medical context under consideration. 
In one setting it will be vital to detect almost all Cancer Informatics 2007:3 208
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cases (e.g. subjects with cancer) while in another it 
will be useful to detect a fraction of them. Suppose 
in this example that a sensitivity of at least 70% is 
desired when the speciﬁ  city is set to 80%. There are 
only 49 genes for which the data suggest this level 
of performance. Randomness of course implies that 
these values are likely biased largely because they 
have been selected as the largest amongst a pool of 
2000 genes. Nevertheless we see that it is helpful 
to at least view the estimated TPR( f0) values. The 
data motivate further evaluation of only the top 49 
genes if the sensitivity criterion is ≥70%.
The descriptive mp-values that correspond 
to the TPR( f0) statistics are also displayed in 
Table 2. The values are very small (<0.05) for the 
top 90 genes, the genes with TPR( f0) estimates 
at or above 0.60. For the remaining 10 differen-
tially expressed genes the mp-values are between 
0.060 and 0.114. Consider the interpretation of the
mp-value for say the 90th gene whose statistic 
TPR(f0) = 0.60. Assuming that all genes ranking at 
or below it are non-differentially expressed, the 
probability that the maximum of those TPR (f0) 
values would exceed 0.60 is only 0.03. This is strong 
evidence against the assumption, and in favor of 
differential expression at the 90th gene. Although 
there is strong evidence that the top 90 genes are dif-
ferentially expressed, we note again that the extent of 
Table2. Simulated data for 50 cases and 50 controls. Genes are ranked using theTPR(0.20). Differentially 
expressed genes ranked 1 through 100. Non-differentially expressed genes ranked 101–2000. P-values based 
on the TPR statistic have superscript T while those based on the AUC statistic have superscript A. BHp-value 
uses the Benjamini-Hochberg (1995) rejection rule while Sp-value uses that of Storey (2002).
Rank  TPR(0.20)  mp-value
T  BHp-value
T  Sp-value
T  AUC  mp-value
A  BHp-value
A  Sp-value
A
1   0.88  0  0  0  0.884  0  0  0
2    0.86 0  0  0  0.880  0  0  0
3    0.86 0  0  0  0.870  0  0  0
4    0.86 0  0  0  0.890  0  0  0
5    0.84 -0  0  0  0.864  0  0  0
6    0.84 0  0  0  0.863  0  0  0
7    0.82 0  0  0  0.869  0  0  0
8    0.8 0  0  0  0.912  0  0  0
9    0.8 0  0  0  0.886  0  0  0
10  0.8 0  0  0  0.901  0  0  0
11  0.8 0  0  0  0.858  0  0  0
12  0.8 0  0  0  0.847  0  0  0
13  0.78 0  0  0  0.869  0  0  0
88  0.6 0.03  0.003  0.003  0.752  0.006  0  0
89  0.6 0.03  0  0  0.721  0.061  0.001  0.001
90  0.6 0.03  0.004  0.004  0.771  0.003  0  0
91  0.58 0.06  0.001  0.001  0.738  0.02  0  0
92  0.58 0.06  0.004  0.004  0.752  0.006 0  0
93  0.58 0.06  0.039  0.037  0.760  0.005 0  0
94  0.56 0.113 0.025  0.024  0.678  0.604 0.021 0.02
95  0.56 0.113 0.005  0.005  0.746  0.01  0  0
96  0.56 0.114 0.018  0.017  0.751  0.006 0  0
97  0.56 0.114 0.014  0.013  0.760  0.005 0  0
98  0.56 0.114 0.005  0.004  0.734  0.023 0.001 0.001
99  0.56 0.113 0.003  0.003  0.736  0.023 0.001 0
100  0.56 0.114 0.007  0.007  0.776  0.002 0  0
101  0.52 0.375  0.010  0.010  0.645  0.985 0.119 0.116
102  0.52 0.375  0.070  0.067  0.718  0.08  0.002 0.002
103  0.46 0.924  0.157  0.150  0.615  1  0.347 0.34
104  0.46 0.925  0.083  0.080  0.653  0.96  0.08  0.079
105  0.44 0.976  0.307  0.293  0.637  0.998 0.169 0.165
106  0.44 0.976  0.791  0.755  0.614  1  0.353 0.346
107 0.44  0.976  0.124 0.118  0.573  1  0.758  0.743
108 0.44  0.976  0.402 0.383  0.576  1  0.727  0.712
109 0.44  0.976  0.321 0.306  0.617  1  0.326  0.32
110 0.42  0.997 0.619 0.591  0.608  1  0.425  0.416Cancer Informatics 2007:3 209
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differential expression seems fairly weak for many 
of these genes.
The adjusted p-values derived from the FDR 
controlling procedures of Benjamin and Hochberg 
(1995) and Storey (2002) are displayed in Table 2. 
These also use the sensitivity statistic, TPR(f0), as 
the basis of analysis. We see that the p-values for 
the two FDR controlling procedures are similar, 
with the Storey p-values slightly smaller as ex-
pected. The Storey p-values are also smaller than 
our mp-values. It appears that rejecting the null 
hypothesis for all genes ranked at or higher than 
the 101st will control the expected FDR below 
5%. In fact the FDR for this decision is equal to 
1/101. Observe that the FDR p-values do not rise 
as sharply as the descriptive mp-values. Indeed, 
there is a remarkably sharp increase in mp-values 
at the 102nd ranked gene with mp-values >0.92 for 
genes ranked at or below the 103rd.
Ordering the genes according to the AUC sta-
tistic gave somewhat more powerful results. All 
but 2 of the 100 differently expressed genes had 
mp-values below 0.05 when analyses were based 
on the AUC statistic. The Storey FDR based p-
values were below 0.05 for 104 genes, yielding 
an FDR of 4/104. For those four false-positive 
errors the mp-values were calculated as between 
0.604 and 0.727 with corresponding AUC values 
between 0.678 and 0.672. These AUC values 
and their descriptive mp-values might be useful 
in deciding not to pursue further study of those 
genes, even though their FDR based p-values 
are <0.05.
In this example, we ﬁ  nd that looking at the 
values of the statistical measure of differential 
expression and the descriptive mp-values leads to a 
more informed decision about which genes to study 
further than simply looking at the error controlling 
p-values alone. We also considered a slightly dif-
ferent simulation example (results not shown), 
where the differences between cases and controls 
were small for the expressed genes. For the 100 
differentially expressed genes the distributions 
of cases were normal with mean 1 and standard 
deviation 2. In this case we ﬁ  nd that although 
the Storey adjusted p-values deemed 79 genes as 
signiﬁ  cant (<0.05), for most of them the extent of 
differential expression is quite weak (only 26 with 
TPR (0.20) ≥ 0.60 and for which the mp-values are 
small). This again underscores the need of taking 
multiple statistical components into consideration 
for gene selection.
Breast cancer data
We now analyze a publicly available cDNA 
microarray dataset from a study of breast cancer 
prognosis reported by Van’t Veer et al. (2002). The 
data consist of approximately 25,000 gene expres-
sion measurements from 44 breast cancer patients 
found to have good prognosis and 34 who had a 
poor prognosis. The goal of the study is to identify 
a subset of genes that are predictive of the prognos-
tic status of breast cancer patients. Although Van’t 
Veer et al. (2002) proceeded to combine data across 
genes for prediction, we are concerned here only 
with the ﬁ  rst step to select a set of genes which are 
each associated with prognosis.
The gene expression measurement is the loga-
rithm of the ratio of the intensities of the red to 
green ﬂ  uorescent dyes, where green dye is used 
for the reference pool and red is used for the 
experimental tissue. In the study of Van’t Veer 
et al. (2002), as a ﬁ  rst step the authors selected some 
5000 genes by applying gene ﬁ  ltering techniques 
that are described in the paper. To investigate 
properties of our new multiple testing procedure, 
we follow the same gene ﬁ  ltering procedure and 
obtain a sample of 4866 genes. We use the AUC 
and TPR(0.20) test statistics to describe how well 
a gene discriminates those subjects that develop 
distant metastases within 5 years (poor prognosis 
status) from those who are disease free beyond 5 
years (good prognosis status). Figure 1 displays the 
distribution of the AUCs and TPR(0.20) statistics 
for the 4866 genes.
Values ordered by TPR(0.20) are displayed in 
Table 3. When thresholds are chosen so that only 
20% of controls exceed the threshold, i.e. FPR = 
20%, the maximum TPR is 67.78%. Certainly none 
of the genes shows promise as an excellent clas-
siﬁ  er on its own. Initially it seemed surprising to 
us that better performance was not observed for at 
least one gene, even by random chance, given that 
almost 5,000 genes were studied. The mp-value 
of 0.009, however, indicates that even if all 5,000 
genes were not differentially expressed, by random 
chance it would be very unlikely that the maximum 
TPR(0.20) value would exceed 67.6%.
The usefulness of the classiﬁ  cation probabili-
ties, TPR(0.20) need to be considered in light of 
potential clinical applications. For example, sup-
pose the idea is to aggressively treat subjects who 
test positive and it is considered justiﬁ  able to treat 
20% of good prognosis patients if an adequate 
fraction of poor prognosis patients are detected Cancer Informatics 2007:3 210
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by the marker. If that ‘adequate’ fraction is 70% 
(i.e. TPR(0.20) = 0.70) then no gene appears to 
satisfy that criterion. If the minimally acceptable 
TPR(0.20) is 60%, then the data suggest this level 
of performance for 17 genes. If it is sufﬁ  cient to 
detect 50% of poor prognosis patients, then 169 
genes have estimated TPR(0.20) values above 
that level.
The descriptive mp-values are <0.05 for 8 
genes and <0.10 for the 17 genes with TPR(0.20) 
≥ 60%. The values do not rise so steeply as in the 
simulated data example, the mp-value being 0.346 
at the gene ranked 52nd, for example. Observe 
that the descriptive mp-values are reasonably 
monotone in the statistic used to calculated them. 
This monotonicity is appealing because drawing 
a line in the list of genes ranked according to the 
descriptive mp-value corresponds to drawing a 
line on the basis of the magnitude of differential 
expression measure.
In contrast, the error rate controlling p-values 
are not monotone in the differential expression 
statistic. The reason for this is that those adjusted 
p-values are defined as functions of the raw 
p-values not directly in terms of the statistics. The 
raw p-value depends on the variability of the sta-
tistic in addition to its magnitude. For example, the 
variability in TPR(0.20) is higher for gene 196 than 
for gene 2348 although they both have the same 
estimates TPR(0.20) = 67.6% (see Pepe (2003) 
page 100 for how these variances are estimated). 
Thus their p-values differ rather dramatically. In 
all, 29 genes have FDR controlling p-values ≤0.05, 
although the corresponding genes rank from sec-
ond to 183rd in terms of the statistics TPR(0.20) 
that are used to calculate the p-values.
8 . 0 7 . 0 6 . 0 5 . 0 4 . 0
0
2
0
0
4
0
0
6
0
0
AUC for all genes
F
r
e
q
u
e
n
c
y
6 . 0 4 . 0 2 . 0 0 . 0
0
2
0
0
6
0
0
1
0
0
0
TPR(0.2) for all genes
F
r
e
q
u
e
n
c
y
Figure1. Histogram of AUC for all genes from the breast cancer study (top); Histogram of TPF(0.2) for all genes from the breast cancer 
study (bottom).Cancer Informatics 2007:3 211
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Variability in the statistic is a concern. Al-
though gene 196 appears to have the same detec-
tion rate as gene 2348, we are much less certain 
about it. The conﬁ  dence interval would be much 
wider. A statistic with less variability is the AUC. 
We see that the AUC for gene 196 is high, (AUC 
= 0.743), that its FDR controlling p-value is very 
small, 0.007, and that the descriptive p-value is 
low, mp-value = 0.169. These facts together with 
its TPR(0.20) value and its associated mp-value 
suggest that it may be worth selecting for further 
study.
Discussion
In exploratory gene expression array studies, the 
idea of considering multiple statistic measures for 
the identiﬁ  cation of differentially expressed genes 
in DNA microarray have been recently explored 
(Hero et al. 2004; Yang et al. 2005). Similarly, 
we emphasize a proper analysis should evaluate 
multiple statistical components. The components 
we have mentioned are the measures of differ-
ential expression (i.e. test statistics), descriptive 
evidence for differential expression (i.e. mp-
values) and the error rate controlling p-values. 
Other aspects of course will also be relevant to 
the rank of gene selection such as biological or 
epidemiological information available about the 
genes themselves.
The choice of statistic for quantifying differen-
tial expression is crucial, but there has been little 
discussion in the literature about this. We ﬁ  nd the 
TPR( f0) particularly appealing since it is easily 
interpreted as the proportion of cases with values 
higher than the normal range of controls, a notion 
that is already familiar in laboratory medicine. 
Nevertheless other choices are valid. The important 
point we wish to make is that the choice deserves 
some thought in the analysis.
The descriptive mp-values that we have proposed 
do not necessarily give rise to procedures for des-
ignating genes as differentially expressed that have 
error rates controlled at speciﬁ  ed levels. Rather, 
they are intuitive and descriptive and naturally 
generalize the univariate p-value concept, Prob(test 
statistic > observed | null), to the multivariate case. 
Other descriptive p-values could be deﬁ  ned. For 
example we also considered
  Prob T t H gg
C
() ()| ≥ ⎡ ⎣ ⎤ ⎦ 0  
which is the probability that under the complete 
null hypothesis the statistic for the g
th ranking gene 
would exceed the value observed. These probabili-
ties tend to be very small, and can be small even if 
genes are not differentially expressed. Therefore 
we do not propose these for use in practice, but 
Table3. Results from the breast cancer prognosis study. Genes are ranked according toTPR(0.20) and result 
displayed for the top 20. The same notation as inTable 2 is used.
Rank Gene#  TRP(0.20) mp-value
T  BHp-value
T  Sp-value
T  AUC  mp-value
A  BHp-value
A  Sp-value
A
1    196  0.676 0.009 0.525  0.245  0.743  0.169  0.04  0.007
2    2348  0.676 0.009 0.073  0.034  0.706  0.611  0.044  0.008
3    208  0.647 0.028 0.243  0.113  0.801  0.002  0.006  0.001
4    4106  0.647 0.028 0.175  0.082  0.792  0.01  0.006  0.001
5    732  0.647 0.028 0.083  0.039  0.791  0.01  0.006  0.001
6    1823  0.647 0.028 0.011  0.005  0.744  0.164  0.04  0.007
7    4682  0.647 0.028 0.152  0.071  0.724  0.363  0.042  0.007
8    1793  0.647 0.028 0.024  0.011  0.709  0.556  0.044  0.008
9    1051  0.618 0.085 0.191  0.089  0.735  0.251  0.042  0.007
10  3816  0.618 0.085 0.595  0.277  0.725  0.353  0.042  0.007
11    3502  0.618 0.085 0.286  0.134  0.723  0.368  0.042  0.007
12  3570  0.618 0.085 0.237  0.110  0.721  0.404  0.042  0.007
13  4610  0.618 0.085 0.191  0.089  0.711  0.529  0.043  0.008
14  2332  0.618 0.085 0.011  0.005  0.700  0.684  0.048  0.009
15  1899  0.618 0.085 0.065  0.030  0.697  0.716  0.049  0.009
16  2603  0.618 0.085 0.243  0.113  0.689  0.818  0.056  0.01
17  4048  0.618 0.085 0.073  0.034  0.686  0.854  0.057  0.01
18 4698 0.588  0.172  0.008  0.004  0.762  0.062  0.032  0.006
19  917  0.588 0.172 0.49  0.228  0.739  0.21  0.04  0.007
20  936  0.588 0.172 0.274  0.128  0.732  0.274  0.042  0.007Cancer Informatics 2007:3 212
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encourage the development of other measures for 
describing strength of evidence for differential 
expression.
Ideally one would summarize differential 
expression at a gene with a conﬁ  dence interval 
for the magni  tude of differential expression. 
Constructing conﬁ  dence intervals is complicated 
by the multiplicity of genes considered simulta-
neously. Moreover the task of ranking genes, in 
effect selects genes according to the esti  mated 
magnitude of differential expression, and conse-
quently induces bias. It is difﬁ  cult to quantify the 
bias, particularly when genes vary in their extent 
of differential expression and in addition genes 
may be correlated.
Finally the deﬁ  nition of conﬁ  dence interval can 
be generalized from the univariate deﬁ  nition in 
several ways. Paralleling deﬁ  nitions of p-values, 
conﬁ  dence intervals that are based on controlling 
error rates of decision rules have been proposed 
(Benjamini and Yekutieli 2005). Alternative, more 
descriptive notions might also be considered in 
the future.
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